European DLB Consortium

Contents

European DLB Consortium

The European DLB Consortium is a collaborative network of neurologists, neuropathologists, geriatricians, geneticists, and clinical researchers focused on Lewy body dementia across Europe. Founded by investigators from major centers in United Kingdom, France, Germany, Italy, and Spain, the Consortium coordinates multicenter studies, harmonizes diagnostic approaches, and interfaces with regulatory agencies including the European Commission, European Medicines Agency, and national health authorities. It interacts with academic institutions such as University College London, Karolinska Institutet, University of Oxford, Università di Milano, and Université Pierre et Marie Curie to translate basic science from laboratories like Max Planck Institute for Brain Research and Institute Pasteur into clinical practice.

History

The Consortium emerged in the early 2000s from meetings held at conferences including the Alzheimer's Association International Conference, the European Neurological Society congress, and workshops at World Health Organization–hosted symposia. Initial founders included investigators affiliated with King's College London, McGill University visiting collaborators, and teams from Hôpital de la Pitié-Salpêtrière and Charité – Universitätsmedizin Berlin. Over time, collaborations expanded to encompass groups linked to Eli Lilly and Company, Pfizer, and academic hubs such as University of Cambridge and University of Helsinki, leading to standardized protocols adopted after consultations with bodies like the European Brain Council and the Wellcome Trust.

Membership spans clinicians and researchers from institutions including University of Edinburgh, Trinity College Dublin, Universidad Complutense de Madrid, Leiden University Medical Center, and University of Copenhagen. Governance typically comprises an executive board with representatives from National Institutes of Health (United States)–partnered centers, chairs elected from centers such as University of Amsterdam and University of Barcelona, and working groups aligned with laboratories at Imperial College London and University of Zurich. The Consortium organizes annual meetings in cities such as Brussels, Paris, Berlin, and Rome and maintains specialty panels on neuropathology, genetics, imaging, and clinical trials incorporating expertise from Roche, Novartis, and nonprofit organizations like Alzheimer's Research UK and Dementia UK.

Key objectives include refining diagnostic criteria in conjunction with panels previously convened by International Conference on Alzheimer's Disease, developing biomarker pipelines with input from centers like Mayo Clinic and Johns Hopkins University, and promoting training programs with universities such as University of Glasgow and Sapienza University of Rome. Activities involve multicenter cohort studies, harmonization of neuroimaging protocols involving teams at Karolinska Institutet and Centre hospitalier universitaire Vaudois, and genetic analyses leveraging consortia-linked resources at Broad Institute and Wellcome Sanger Institute. The group also runs outreach to patient organizations including Alzheimer's Society (UK), European Federation of Neurological Associations, and national societies like the German Neurological Society.

The Consortium has produced multicenter articles in journals such as The Lancet Neurology, Brain (journal), Neurology (journal), JAMA Neurology, and Annals of Neurology. Research themes include clinicopathological correlations with contributions from University of Pennsylvania neuropathology teams, imaging studies with neuroradiology groups at Mayo Clinic and Addenbrooke's Hospital, and genetics papers drawing on cohorts from University of Copenhagen and University of Antwerp. Publications often reference biomarker studies employing assays developed with collaborators at Erasmus MC, University of Tübingen, and the National Institute on Aging. The Consortium's datasets have been used in meta-analyses by researchers affiliated with Columbia University, Harvard Medical School, and University of British Columbia.

Guideline efforts have aligned with diagnostic frameworks from working groups whose members are associated with International Parkinson and Movement Disorder Society, European Academy of Neurology, and Alzheimer's Disease International. Recommendations address clinical criteria, neuropsychological testing protocols from laboratories at University of California, San Francisco and McMaster University, and pharmacologic management drawing on evidence compiled by teams at University of Milan Bicocca and University of Bonn. The Consortium's influence is evident in national guideline updates by agencies such as the National Institute for Health and Care Excellence and the incorporation of recommendations into training programs at University of Leiden and University of Oslo.

Funding and collaborations involve public and private partners including the European Commission Horizon 2020 programs, grants from the European Research Council, philanthropic support from the Alzheimer's Society (UK), and industry partnerships with Biogen, Roche, and GE Healthcare. Cross-consortium projects have interfaced with initiatives like the Human Brain Project, the EU Joint Programme – Neurodegenerative Disease Research, and the Global Alzheimer’s Platform Foundation. Collaborative networks include ties to registries and biobanks at UK Biobank, Scandinavian Twin Registry, and university hospital collections at Charité and AP-HP institutions.

Category:Neuroscience organizations Category:Neurology